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Antinuclear auto-antibodies are a hallmark of systemic lu-
pus erythematosus. Based on the characteristics of these
auto-antibodies (somatic mutation, restricted use of certain
VH andVL genes, high avidity IgG antibodies, common id-
iotypes), lupus is regarded as an auto-antigen-driven T-cell-
dependent autoimmune disease [1]. It is generally assumed,
however, that the produced auto-antibodies are pivotal for
the development of tissue lesions, and hence also B cells are
necessary for disease development. Indeed, MRL/lpr lupus
mice, which due to a certain genetic manipulation lack B
cells, develop neither glomerulonephritis nor vasculitis [2].
Therefore, in lupus, B cells represent amajor target for treat-
ment. Cyclophophosphamide, an effective, although toxic,
drug in the treatment of lupus nephritis depletes B cells (but
also other cell types) and quickly suppresses auto-antibody
formation. More recently, a number of new treatment op-
tions became available in lupus, all directed at the B cell
[3]. These therapies have different mechanisms to influ-
ence B-cell function: (i) depletion by anti-CD20 antibodies
(rituximab, ocrelizumab); (ii) reduction of anti-DNA titres
(LJP394/abetimus); (iii) blockade of T-cell co-stimulation
(CTLA4-Ig: abatacept and belatacept) and (iv) blockade of
B-cell stimulation via CD40 or the cytokine BLys (beli-
mumab or atacicept).
Experience with these B cell-targeted therapies has
taught that treatment efficacy goes beyond the reduction
of auto-antibody levels and is in part due to silencing of
B cells. This also affects other B-cell functions important
for development and persistence of autoimmunity. How-
ever, these therapies hardly influence long-lived plasma
cells. These long-lived plasma cells are important in lu-
pus, because they represent a major fraction of the auto-
antibody-producing B cells. Since they are a difficult target
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to treat, they are important for the perpetuation and flares
of the autoimmune disease. Recently, Neubert and col-
leagues have described a new approach, which also attacks
these long-lived plasma cells [4]. They evaluated the effect
of bortezomib (BTZM) on lupus nephritis in two mouse
models of spontaneous lupus namely the (NZBxNZW)F1
and MRL/lpr model. BTZM has been used successfully
in relapsing or refractory multiple myeloma [5]. BTZM
is an inhibitor of the 26S proteasome, thereby inhibiting
the degradation of misfolded, defective and regulatory pro-
teins. This inhibition leads to the activation of the terminal
unfolded protein response (UPR) that induces apoptosis of
the cell. Susceptibility of cells for BTZM is correlated with
the extent of protein production, and in myeloma B cells,
with the extent of Ig production [6]. This finding raised
the idea whether this might also be true for non-malignant
B cells with a high Ig production. This was indeed the
case. BTZM (0.75 mg/kg body weight given twice at 0 and
36 h) in ovalbumin-immunized BALB/c mice led after
48 h to a reduction of B cell numbers in the spleen of 60%
and in the bone marrow of 80%. In the (NZBxNZW)F1
lupus strain, BTZM induced after 48 h a 96% reduction of
splenic B cells and 88% of bone-marrow B cells and an
almost complete disappearance of anti-dsDNA-producing
B cells. With proliferation markers it was determined that
both short- and long-lived plasma cells were depleted.
This effect of BTZM on long-lived plasma cells was much
more efficient than that achieved by dexamethasone or cy-
clophosphamide. These two latter drugs also depleted T
cells, macrophages and dendritic cells in contrast to BTZM.
As in tumour cells, BTZM exerts its action in B cells by
creating a pro-apoptotic milieu by activating the termi-
nal UPR and by inhibiting activation of the anti-apoptotic
NFκB. Of potential clinical relevance is the observation
that BTZM given twice weekly intravenously in a dose of
0.75 mg/kg body weight for 10 months prevented forma-
tion of anti-dsDNA antibodies, proteinuria and histologi-
cal signs of glomerulonephritis and prolonged survival in
(NZBxNZW)F1 mice. In a subsequent study, BTZM treat-
ment proved also effective when started in (NZBxNZW)F1
mice that already had anti-dsDNA antibodies and pro-
teinuria. BTZM reverted anti-dsDNA antibody formation
and proteinuria. Similar results were obtained in another
murine lupusmodel, theMRL/lpr strain. To evaluate overall
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immunosuppression, immunizations with T-cell-dependent
and T-cell-independent antigens were performed. During
BTZM treatment, the response to T-cell-dependent antigens
was severely decreased butwas normal if immunizationwas
carried out 5 days after cessation of BTZM treatment. The
response to T-cell-independent antigens was unimpaired,
even during BTZM treatment, consistent with the obser-
vation that BTZM does not affect marginal zone B cells,
which are responsible for this IgM response.
What are the clinical perspectives of these findings with
BTZM in spontaneous lupus mouse models? In the recent
years, experience has been obtained with BTZM in the
treatment of patients with multiple myeloma, mantle cell
lymphoma and certain solid tumours [7].
However, the doses used in these clinical studies were 1–
1.5 mg/m2 per administration. In the lupus mouse studies,
much higher dosages were used of 0.75mg/kg body weight.
Although it is very difficult, if not impossible, to extrapolate
dosing in mice to patients, it remains to be determined
whether dosages used in multiple myeloma patients are
also effective in lupus patients. Also from the experience in
multiplemyeloma patients, it is clear that BTZMhas serious
adverse events [5]. Early discontinuation because of side
effects was necessary in 37% of the patients. These side
effects include polyneuropathy (36%), thrombocytopenia
(35%) and gastrointestinal complaints (57%).
So it remains to be determined whether this high inci-
dence of side effects precludes the use of BTZM in lu-
pus nephritis because recently alternatives for cyclophos-
phamide became available like MMF and anti-CD20 with
a much better tolerability.
Therefore, at present it is difficult to predict whether
BTZMwill become a therapeutic option in the treatment of
severe lupus.A potential cohort of patients could form those
patients in whom stem cell transplantation is considered
because of the severity and uncontrollable nature of the
disease. In contrast to stem cell transplantation [8,9], BTZM
has the capacity to attack long-lived plasma cells [4].
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